The SIESTA Trial: A Randomized Study Investigating the Efficacy, Safety, and Tolerability of Acupressure versus Sham Therapy for Improving Sleep Quality in Patients with End-Stage Kidney Disease on Hemodialysis
Table 2
Primary (PSQI) and secondary (QOL) outcomes at four weeks of treatment group (adjusted for baseline values).
Outcome
Intervention ()
Control ()
Difference (intervention − control) [95% CI]
value
PSQI global scores
7.62
7.42
0.19 [−1.32 to 1.70]
0.80
PSQI subscales
Sleep duration
1.06
1.08
−0.01 [−0.40 to 0.38]
0.95
Habitual sleep efficiency
1.12
1.23
−0.11 [−0.72 to 0.50]
0.73
Subjective sleep quality
0.84
0.80
0.04 [−0.33 to 0.42]
0.82
Sleep latency
1.66
1.48
0.18 [−0.44 to 0.81]
0.55
Daytime dysfunctions
0.95
0.95
0.00 [−0.50 to 0.49]
0.99
Sleep disturbances
1.58
1.56
0.02 [−0.31 to 0.35]
0.90
Use of sleep medication
QOL
MCS
47.41
51.30
−3.88 [−8.63 to 0.87]
0.11
PCS
44.39
41.94
2.45 [−1.69 to 6.58]
0.24
PSQI, Pittsburgh Sleep Quality Index; QOL, quality of life; MCS, mental component summary; PCS, physical component summary. Note. Results for subscale “use of sleep medication” were not included due to a lack of variability in the data.
